| Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. | |
| | |
MedLine Citation:
|
PMID: 12807341 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: An 8-week randomized, reference-controlled, double-blind, multi-centre clinical trial investigated Kava-Kava LI 150 in Generalized Anxiety Disorder (GAD; ICD-10: F41.1). METHOD: 129 out-patients received either 400 mg Kava LI 150, 10 mg Buspirone or 100 mg Opipramol daily for 8 weeks. At week 9, subjects were seen to check for symptoms of withdrawal or relapse. Primary outcome measures comprised the HAMA scale and the proportion of responders at week 8. Secondary measures were the Boerner Anxiety Scale (BOEAS), SAS, CGI, a self-rating scale for well-being (Bf-S), a sleep questionnaire (SF-B), a quality-of-life questionnaire (AL) and global judgements by investigator and patients. RESULTS: In 127 patients (ITT) no significant differences could be observed regarding all efficacy and safety measures. About 75% of patients were classified as responders (50% reduction of HAMA score) in each treatment group, about 60% achieved full remission. CONCLUSION: Kava-Kava LI150 is well tolerated and as effective as Buspirone and Opipramol in the acute treatment of out-patients suffering from GAD. |
| | |
Authors:
|
R J Boerner; H Sommer; W Berger; U Kuhn; U Schmidt; M Mannel |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Phytomedicine : international journal of phytotherapy and phytopharmacology Volume: 10 Suppl 4 ISSN: 0944-7113 ISO Abbreviation: Phytomedicine Publication Date: 2003 |
Date Detail:
|
Created Date: 2003-06-16 Completed Date: 2003-08-14 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9438794 Medline TA: Phytomedicine Country: Germany |
Other Details:
|
Languages: eng Pagination: 38-49 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany. reinhard.boerner@psy.med.uni-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anti-Anxiety Agents / administration & dosage, therapeutic use* Anxiety Disorders / drug therapy*, pathology Buspirone / administration & dosage, therapeutic use Double-Blind Method Drug Administration Schedule Female Germany Humans Kava* Male Manifest Anxiety Scale Middle Aged Opipramol / administration & dosage, therapeutic use Phytotherapy* Plant Extracts / administration & dosage, therapeutic use* Quality of Life Questionnaires Sleep Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Anxiety Agents; 0/LI 150; 0/Plant Extracts; 315-72-0/Opipramol; 36505-84-7/Buspirone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Topical treatment of atopic dermatitis with St. John's wort cream--a randomized, placebo controlled,...
Next Document: Bacterial deconjugation of arbutin by Escherichia coli.